Department of Clinical Medicine, Hangzhou City University School of Medicine, Hangzhou, China.
Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Front Immunol. 2024 Aug 13;15:1410519. doi: 10.3389/fimmu.2024.1410519. eCollection 2024.
Acute lymphoblastic leukemia (ALL) is a prevalent malignancy affecting the hematopoietic system, encompassing both B-cell ALL (B-ALL) and T-cell ALL (T-ALL). T-ALL, characterized by the proliferation of T-cell progenitors in the bone marrow, presents significant treatment challenges, with patients often experiencing high relapse rates and poor long-term survival despite advances in chemotherapy and hematopoietic stem cell transplantation (HSCT). This review explores the pathogenesis and traditional treatment strategies of T-ALL, emphasizing the promising potential of chimeric antigen receptor (CAR) technology in overcoming current therapeutic limitations. CAR therapy, leveraging genetically modified immune cells to target leukemia-specific antigens, offers a novel and precise approach to T-ALL treatment. The review critically analyzes recent developments in CAR-T and CAR-NK cell therapies, their common targets, optimization strategies, clinical outcomes, and the associated challenges, providing a comprehensive overview of their clinical prospects in T-ALL treatment.
急性淋巴细胞白血病（ALL）是一种常见的影响造血系统的恶性肿瘤，包括 B 细胞 ALL（B-ALL）和 T 细胞 ALL（T-ALL）。T-ALL 的特征是骨髓中 T 细胞前体的增殖，尽管化疗和造血干细胞移植（HSCT）取得了进展，但患者仍经常经历高复发率和较差的长期生存。本综述探讨了 T-ALL 的发病机制和传统治疗策略，强调嵌合抗原受体（CAR）技术在克服当前治疗局限性方面的广阔前景。CAR 疗法利用基因修饰的免疫细胞靶向白血病特异性抗原，为 T-ALL 治疗提供了一种新颖而精确的方法。该综述批判性地分析了 CAR-T 和 CAR-NK 细胞疗法的最新进展、它们的常见靶点、优化策略、临床结果以及相关挑战，全面概述了它们在 T-ALL 治疗中的临床前景。
